The Effect of Arylquinoline-Based EGFR and FAK Kinase Inhibitors on the Activity of Major Cytochrome P450 Enzymes [0.03%]
基于arylquinoline的EGFR和FAK激酶抑制剂对主要细胞色素P450酶活性的影响
Fawzy Elbarbry,Michael Espiritu,Bethany Hecker et al.
Fawzy Elbarbry et al.
Background and objective: The cytochrome P450 (CYP) system plays a central role in drug metabolism and pharmacokinetic variability, influencing drug-drug interaction risk. The newly synthesized 4-propoxy-2-arylquinoline d...
Differences in Physiologically Based Pharmacokinetic Predictions between Software Platforms Can Be Clinically Relevant: Cases of Levornestrogel and Ethinylestradiol Concentrations with SIMCYP versus PK-Sim from a User Perspective [0.03%]
从使用者角度出发，基于生理的药代动力学预测中软件平台对利凡诺凝胶和乙炔雌二醇浓度的影响：SIMCYP与PK-Sim对比研究
Camille Massaux,Jean-Michel Dogné,Flora Tshinanu Musuamba
Camille Massaux
Background and objective: Physiologically based pharmacokinetic models are increasingly applied in drug development and regulatory submissions. Differences in predictions between software platforms may challenge reproduci...
Predicting Ketamine Exposure in Pediatric Status Epilepticus: A Pharmacokinetic-Machine Learning Approach [0.03%]
儿科癫痫持续状态氯胺酮暴露的预测：药代动力学-机器学习方法
Adeboye O Bamgboye,Lisa D Coles,Sílvia M Illamola et al.
Adeboye O Bamgboye et al.
Background and objective: Status epilepticus is a life-threatening neurological emergency. Ketamine combined with levetiracetam is a promising therapy being investigated for established status epilepticus. Early drug expo...
Vancomycin Pharmacokinetics in Obese Patients: Insights from Bayesian Modeling [0.03%]
贝叶斯方法用于肥胖患者万古霉素药代动力学分析的见解
Fawzy Elbarbry,Tyler Thilavanh,Sarah White et al.
Fawzy Elbarbry et al.
Background: Optimal vancomycin dosing in obese patients remains challenging due to altered pharmacokinetics and the variable relationship between trough concentrations and therapeutic exposure. ...
Pharmacokinetics of Landiolol and Its Metabolite M1 During Renal Replacement Therapy in Septic Shock Patients: A Sub-Study of the Landi-SEP Trial [0.03%]
LANDIOLOL及其代谢产物M1在SeptiShock患者血液透析中的药代动力学：来自LANDIOLOL研究的子研究
Sebastian Rehberg,Rainer Borgstedt,Sandra Frank et al.
Sebastian Rehberg et al.
Background and objective: Landiolol, an ultra-short-acting β-blocker, is commonly used to manage tachyarrhythmias, including critically ill patients requiring renal replacement therapy (RRT). Pharmacokinetic (PK) data fo...
Pharmacokinetics and Bioequivalence of Propafenone Hydrochloride Tablets under Fasting Conditions in Healthy Subjects [0.03%]
空腹状态下盐酸普鲁卡因胺片在中国健康受试者体内的药代动力学及生物等效性研究报告
Yi Zhang,Meixia Hua,Lijie Du et al.
Yi Zhang et al.
Background and objective: This study evaluated the pharmacokinetic characteristics, bioequivalence, and safety of propafenone hydrochloride tablets under fasting conditions in healthy Chinese subjects. ...
Optimization of Dosing Regimens for Plasminogen Activation Inhibitor BT-114143 Using a Small Molecule TMDD Population PK and PD Model in Healthy Subjects [0.03%]
基于小分子TMDD的群体PK/PD模型优化健康受试者中PAI-BT-114143给药方案的研究
Min Li,Yafen Li,Shaomei Zeng et al.
Min Li et al.
Background and objective: BT-114143 is a novel, small-molecule antifibrinolytic agent that promotes hemostasis by inhibiting the conversion of plasminogen to plasmin. Due to its strong binding to this target, the drug exh...
Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Fremanezumab in Children and Adolescents with Migraine [0.03%]
儿童和青少年偏头痛患者erasinezumab的药代动力学、药效学、有效性和安全性
Luigi Francesco Iannone,Marina Romozzi,Laura Papetti et al.
Luigi Francesco Iannone et al.
Migraine affects up to 11% of children and adolescents, leading to substantial disability through school absenteeism, cognitive impairment, and reduced quality of life. Traditionally, preventive treatment options for this population have be...
Role of Pharmacogenetics on Tramadol Pharmacokinetics: A Population Pharmacokinetic Model [0.03%]
药理遗传学在曲马多药代动力学中的作用：群体药代动力学模型分析
Paula Soria-Chacartegui,Gudrun Würthwein,Pablo Zubiaur et al.
Paula Soria-Chacartegui et al.
Background and objective: Tramadol is a widely used opioid, and pharmacogenetics is partially responsible for the variability in its response. The objective was to develop a tramadol population pharmacokinetic (popPK) mod...